Nanotherapy offers hope for renal cell carcinoma
By LAURA WADSTEN | October 4, 2018Kidney cancer is among the 10 most common cancers in both men and women. In adults, renal cell carcinoma is the most common type of kidney cancer. The American Cancer Society predicts that there will be 65,340 new diagnoses and 14,970 deaths due to renal cell carcinoma in 2018. A novel treatment has been developed that may be able to reverse drug resistance in renal cell carcinoma, using nanotherapy in combination with chemotherapeutic drugs.















